Healthcare / Medical DevicesShanghai
$27.23
-0.03 (-0.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-72.5M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.7B
P/E
118.4x
↑EV/EBITDA
60.7x
↑ROE
2.8%
↑Gross Margin
43.7%
↓Debt/Equity
0.11
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.3%
FCF CAGR
—
FCF margin
20.9%
FCF / Net income
2.35x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $345.5M · net income $30.8M · FCF $72.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $345.5M | $345.5M | $318.3M | $307.6M | $322.4M |
| Net Income | $30.8M | $30.8M | $32.5M | $60.0M | $115.7M |
| EBITDA | $59.0M | $59.0M | $60.1M | $73.8M | $135.4M |
| EPS | 0.23 | 0.23 | 0.24 | 0.44 | 0.85 |
| Gross Margin | 43.7% | 43.7% | 39.1% | 54.8% | 59.6% |
| Operating Margin | 16.8% | 16.8% | 10.9% | 30.4% | 41.0% |
| Net Margin | 8.9% | 8.9% | 10.2% | 19.5% | 35.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.11 | 0.11 | 0.12 | 0.05 | — |
| Current Ratio | 2.60 | 2.60 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $72.3M | $72.3M | $-118.9M | $-72.5M | $-104.0M |
| Returns | |||||
| ROE | 2.8% | 2.8% | 3.0% | 5.7% | 11.5% |
| Valuation | |||||
| P/E | 118.39 | 118.39 | 76.17 | 85.61 | 40.09 |
| EV/EBITDA | 60.74 | 60.74 | 41.23 | 66.64 | 31.55 |
| P/B | 3.30 | 3.30 | 2.31 | 4.88 | 4.62 |
| Growth & Yield | |||||
| Revenue Growth | 8.5% | 8.5% | 3.5% | -4.6% | — |
| EPS Growth | -4.2% | -4.2% | -45.5% | -48.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
119.0%
EPS terminal req.
$2.42
Spread vs growth
-123.2%
5Y implied EPS CAGR
66.3%
EPS terminal req.
$2.92
Spread vs growth
-70.4%
10Y implied EPS CAGR
35.2%
EPS terminal req.
$4.71
Spread vs growth
-39.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+34.5%
Start / end P/E
84.4x → 118.4x
EPS bridge
0.24 → 0.23
Residual
-1.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.